Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory DiseasesGlobeNewsWire • 08/26/24
Compared to Estimates, Regeneron (REGN) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 08/01/24
Regeneron (REGN) Tops on Q2 Earnings, Eylea HD, Dupixent Fuel SalesZacks Investment Research • 08/01/24
Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative InnovationGlobeNewsWire • 07/31/24
Regeneron Pharmaceuticals Inc Investors With Losses Are Urged To Contact The Schall Law Firm As It Initiates An Investigation Into AllegationsAccesswire • 07/30/24
Countdown to Regeneron (REGN) Q2 Earnings: Wall Street Forecasts for Key MetricsZacks Investment Research • 07/29/24
Regeneron Pharmaceuticals Inc Investors With Losses Are Encouraged To Contact The Schall Law Firm As They Initiate An Investigation Into AllegationsAccesswire • 07/26/24